CREDENCE: Significant Victory for Diabetic Kidney Disease

Ashish Verma; Ankit B Patel; Ashish Upadhyay; Sushrut S Waikar

doi:10.1016/j.tem.2020.04.002

CREDENCE: Significant Victory for Diabetic Kidney Disease

Trends Endocrinol Metab. 2020 Jun;31(6):391-393. doi: 10.1016/j.tem.2020.04.002. Epub 2020 Apr 21.

Authors

Ashish Verma¹, Ankit B Patel², Ashish Upadhyay³, Sushrut S Waikar⁴

Affiliations

¹ Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: Averma8@bwh.harvard.edu.
² Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
³ Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
⁴ Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA, USA. Electronic address: swaikar@bu.edu.

PMID: 32327275
DOI: 10.1016/j.tem.2020.04.002

Abstract

Diabetic kidney disease (DKD), the most common cause of end-stage kidney disease (ESKD), has significant morbidity and mortality, particularly from cardiovascular complications. The CREDENCE (canagliflozin and renal events in diabetes with established nephropathy clinical evaluation) trial reported by Perkovic and collaborators has led to an emergence of a new class of therapeutic agents for slowing DKD progression.

Publication types

Review

MeSH terms

Cardiovascular Diseases / drug therapy*
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Nephropathies / drug therapy*
Diabetic Nephropathies / etiology
Humans
Sodium-Glucose Transporter 2 Inhibitors / pharmacology*

Substances

Sodium-Glucose Transporter 2 Inhibitors